Pharma/Biotech General Discussion


Trump to Allow Americans to Get Drugs From Canada?

2 months ago

Trump is usually a clown but he ends up doing some rational things every so often.


The Trump administration is exploring ways to allow Americans to import cheaper prescription drugs from Canada, the Department of Health and Human Services said on Wednesday.

The move holds out the promise of lower-cost prescription drugs, but many details would still need to be worked out. The administration will look into new rules to allow states, pharmacies and other parties to bring in drugs from Canada as par…

Biosimilars being delayed cost US healthcare system $7.6B

3 months ago

A new whitepaper published by the Association for Accessible Medication's Biosimilars Council found that patent tactics preventing biosimilars from entering the market have cost the U.S. healthcare system $7.6 billion since 2015.

Although the FDA has approved 20 biosimilars, only seven are available for patient use in the U.S.

The paper claims, "This is a direct result of the patent schemes used by some brand-name pharmaceutical companies to maintain their lucrative product pricing monopolies be…

FDA Grants Fast Track Designation for FARXIGA in Heart Failure

13 hours ago

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF).

Vylessi Approved to treat loss of sexual desire in women

3 months ago

Brutal takedown from Stat:

The Vyleesi data don’t prove me wrong. Only 8% more of the women who injected themselves with the drug compared to a placebo shot had a modest increase in sexual desire. On a separate sexual “distress” score, the difference between Vyleesi and placebo was 4%.

Women struggling with sexual dysfunction, like men struggling with sexual dysfunction, deserve safe, efficacious treatments; unfortunately, the market has not given women many options. Vyleesi did not help wom…

​Karyopharm layoffs

3 months ago

The layoffs were poorly executed and from the business perspective things should have never been executed this way – there was no need for it.

I’ve worked here for a while and will be leaving on my own – people and management have changed and not for the better. The work life balance can be better and there is a ton of passive aggressive behaviors happening at Karyopharm.

If you look at the recent round of layoffs you can be sure there will be more to come. And they will tell you sweet thin…

Intact Vascular to Announce One-Year Data from TOBA III Clinical Trial

13 hours ago

​Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that the one-year data from its Tack Optimized Balloon Angioplasty (TOBA) III clinical trial will be presented during the High Impact Clinical Research session of the 31st

New Jersey Relaxes Physician Payment Rules

4 months ago

According to STAT, New Jersey is being one of the more reasonable states in how they will restrict gifts and payments made to physicians by drug companies.

Last year the rule went into effect by placing a $10,000 annual cap on what physicians can earn from drugmakers. There was also a $15 cap on “modest meals” for educational events which is ridiculous.

The revision would keep the 10k cap but increase dinners to $30 from $15. The extra $15 is better but still kind of low. Most physicians are…

Now Pharma Reps are Wearing Scrubs

4 months ago

Pharma reps have finally seen the light. Reps in scrubs equal easier access than if they're in a suit.

Nostrum Laboratories Raises Cold Medicine Price by 326%

4 months ago

According to the Financial Times. Nostrum Laboratories raised the price of their prescription cold medicine by 326%. A 473mL bottle of promethazine and codeine now costs $170.55 with other drug companies selling the same product for $27 and $12.35. The CEO said he hopes their competitors raise their prices so they can sell more. I guess he doesn't realize that a higher list price means more out of pocket costs for the patient.

You can read the full report here.

National Lipid Association’s New Position Statement on Use of Icosapent Ethyl in High and Very-High-Risk Patients Recognizes Importance of Addressing Residual Cardiovascular Risk in Patients on Statins

14 hours ago

​Amarin Corporation plc (NASDAQ: AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that the National Lipid Association (NLA) has issued a position statement recognizing the cardiovascular risk-lowering effects of icosapent ethyl based on the landmark REDUCE-IT cardiovascular outcomes study.

Passive Immunotherapy and Cancer Therapies

5 months ago

Cancer is characterized by an abnormal cell growth. Until recently, cancer therapies were mostly based on surgery, radiation and non-targeted chemotherapy. This latter technique generally induces important undesirable effects as it kills indistinctively a large number of fast-growing cells, including healthy ones. The increasing success of immunothera…

Snapchat wants pharma companies to advertise in the app

5 months ago

Snap, parent company of social media app Snapchat, is trying to convince pharma companies to advertise products targeted for younger audiences in the app.

A report from CNBC said the company sent sales reps to the DigiPharma Connect conference to present on direct-to-consumer ads.

The company thinks their platform is ideal because it's a more comfortable place and users don't have the function to leave comments. Their younger audience is also a plus with 34% of its 81 million U.S. users being be…

FiercePharma's Top Pharma Companies in the World

5 months ago

Of course J&J is at the top of the list when they don't pay their reps at the going market rate. Save a lot of money that way.

Celgene Announces Phase 3 QUAZAR AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints

3 days ago

Celgene Corporation (NASDAQ: CELG) today announced top-line results from the international phase 3, randomized, double-blind, placebo-controlled study, QUAZAR AML-001. The study evaluated the efficacy and safety of investigational therapy CC-486 as maintenance therapy in patients with newly diagnosed acute myeloid leukemia (AML)

Best Pharma Swag

5 months ago

There's no difference between a pharma and medical device rep during trade shows. In fact, most device jobs are starting to resemble pharma jobs so what does it matter....

Loading...